Skip to main content

Table 1 Basic characteristics according to treatment prior to surgery for patients with LARC (N=332)

From: Postoperative recurrence in locally advanced rectal cancer: how does neoadjuvant treatment affect recurrence pattern?

 

Overall (N=332)

Surgery alone (N=232)

nCRT (N=51)

NAC (N=49)

Variables

N

%

N

%

N

%

N

%

Median age (range)

66 (21–90)

68 (28–90)

61 (27–79)

64 (21–81)

Gender

 Male

218

65.7

147

63.4

35

68.6

36

73.5

 Female

114

34.3

85

36.6

16

31.4

13

26.5

Clinical T classification

 <cT2

35

10.5

32

13.8

2

3.9

1

2.0

 cT3

223

67.2

157

67.7

32

62.8

34

69.4

 cT4

74

22.3

43

18.5

17

33.3

14

28.6

Clinical N classification

 cN0

212

63.9

139

59.9

42

82.4

31

63.3

 cN1

92

27.7

72

31.0

7

13.7

13

26.5

 cN2

28

8.4

21

9.1

2

3.9

5

10.2

mr-CRM involvement

96

28.9

33

14.2

38

74.5

25

51.0

Clinical stage

 cStage II

96

28.9

84

36.2

8

15.7

4

8.2

 cStage III

236

71.1

148

63.8

43

84.3

45

91.8

Clinical LPLN swelling

67

20.2

26

11.2

25

49.0

16

32.4

Tumor locationa

 Upper rectum

148

44.6

128

55.2

4

7.8

16

32.7

 Lower rectum

178

53.6

100

43.1

45

88.2

33

67.3

 Anal canal

6

1.8

4

1.7

2

3.9

0

0.0

Surgical procedure

 Anterior resection

215

64.8

170

73.3

14

27.5

31

63.3

 Abdominoperineal resection

52

15.7

26

11.2

16

31.4

0

20.4

 Intersphincteric resection

46

13.9

22

9.5

18

35.3

6

12.2

 Hartmann procedure

14

4.2

12

5.2

2

3.9

0

0.0

 Total pelvic exenteration

5

1.5

2

0.9

1

2.0

2

4.1

Simultaneous LPLN dissection

67

20.2

26

11.2

25

49.0

16

32.4

Pathological T classification

 p-, ypT0,Tis

17

5.1

1

0.4

12

23.5

4

8.2

 p-, ypT1

20

6.0

17

7.3

3

5.9

0

0.0

 p-, ypT2

75

22.6

54

23.3

10

19.6

11

22.5

 p-, ypT3

184

55.4

129

55.6

24

47.1

31

63.3

 p-, ypT4

36

10.8

31

13.4

2

3.9

3

6.1

Pathological stage

 0–I

83

25.0

50

21.6

20

39.2

13

26.5

 II

129

38.9

89

38.4

22

43.1

18

36.7

 III

120

36.1

93

40.1

9

17.6

18

36.7

Pathological LPLN involvement

12

3.6

4

1.7

3

5.9

5

10.2

R0 resection

321

96.7

224

96.6

51

100

46

93.9

Pathological CRM involvement

11

3.3

8

3.6

0

0.0

3

6.1

Adjuvant chemotherapy

 None

181

54.5

160

69.0

15

29.4

6

12.2

 Dubletsb

86

25.9

37

16.0

24

47.1

25

51.0

 Fluoropyrimidinesc

62

18.7

34

14.7

11

21.6

17

34.7

 Unknown

1

0.9

1

0.4

1

2.0

1

2.0

  1. aDefined as follows: upper rectum (between the lower level of the S2 vertebra and the peritoneal reflection), lower rectum (between the peritoneal reflection and the upper level of the puborectal sling), and anal canal (between the upper level of the puborectal sling and the anal verge). (According to the Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma)[9]
  2. bFOLFOX, CAPOX, FOLFIRI, SOX, or IRIS
  3. cInfusion 5-FU/LV, capecitabine, or S-1
  4. Abbreviations: LPLN Lateral pelvic lymph node, mr-CRM MRI-assessed circumferential resection margin, NAC neoadjuvant chemotherapy, nCRT Neoadjuvant chemoradiotherapy
Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us